These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31664064)

  • 21. Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration.
    Papadopoulos A; Ribera A; Mavrogenis AF; Rodriguez-Pardo D; Bonnet E; Salles MJ; Dolores Del Toro M; Nguyen S; Blanco-García A; Skaliczki G; Soriano A; Benito N; Petersdorf S; Pasticci MB; Tattevin P; Tufan ZK; Chan M; O'Connell N; Pantazis N; Kyprianou A; Pigrau C; Megaloikonomos PD; Senneville E; Ariza J; Papagelopoulos PJ; Giannitsioti E;
    Int J Antimicrob Agents; 2019 Mar; 53(3):294-301. PubMed ID: 30395988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis.
    Chien HT; Lin YC; Sheu CC; Hsieh KP; Chang JS
    Int J Antimicrob Agents; 2020 Mar; 55(3):105889. PubMed ID: 31923573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili A; Izanloo A; Rastegar M
    Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections.
    Cai B; Cai Y; Liew YX; Chua NG; Teo JQ; Lim TP; Kurup A; Ee PL; Tan TT; Lee W; Kwa AL
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4013-22. PubMed ID: 27090177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.
    Paul M; Lador A; Grozinsky-Glasberg S; Leibovici L
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003344. PubMed ID: 24395715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of different polymyxin-containing regimens for the treatment of pneumonia caused by multidrug-resistant gram-negative bacteria: a systematic review and network meta-analysis.
    Zhou Y; Wang G; Zhao Y; Chen W; Chen X; Qiu Y; Liu Y; Wu S; Guan J; Chang P; Liu Y; Liu Z
    Crit Care; 2024 Jul; 28(1):239. PubMed ID: 39004760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative microorganisms in children?
    Ozsurekci Y; Aykac K; Cengiz AB; Bayhan C; Sancak B; Karadag Oncel E; Kara A; Ceyhan M
    Diagn Microbiol Infect Dis; 2016 Jun; 85(2):233-8. PubMed ID: 27041107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia.
    Parchem NL; Bauer KA; Cook CH; Mangino JE; Jones CD; Porter K; Murphy CV
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1433-9. PubMed ID: 27230510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymyxin Monotherapy vs. Combination Therapy for the Treatment of Multidrug-resistant Infections: A Systematic Review and Meta-analysis.
    Samal S; Samir SB; Patra SK; Rath A; Dash A; Nayak B; Mohanty D
    Indian J Crit Care Med; 2021 Feb; 25(2):199-206. PubMed ID: 33707900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy for extensively-drug resistant gram-negative bacteria.
    Karaiskos I; Antoniadou A; Giamarellou H
    Expert Rev Anti Infect Ther; 2017 Dec; 15(12):1123-1140. PubMed ID: 29172792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of mortality in bloodstream infections caused by multidrug-resistant gram-negative bacteria: 4 years of collection.
    Wang W; Jiang T; Zhang W; Li C; Chen J; Xiang D; Cao K; Qi LW; Li P; Zhu W; Chen W; Chen Y
    Am J Infect Control; 2017 Jan; 45(1):59-64. PubMed ID: 27765296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
    Falagas ME; Mavroudis AD; Vardakas KZ
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy for treatment of infections with gram-negative bacteria.
    Tamma PD; Cosgrove SE; Maragakis LL
    Clin Microbiol Rev; 2012 Jul; 25(3):450-70. PubMed ID: 22763634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidrug resistance and extended-spectrum beta-lactamase producing Gram-negative bacteria from three Referral Hospitals of Amhara region, Ethiopia.
    Moges F; Gizachew M; Dagnew M; Amare A; Sharew B; Eshetie S; Abebe W; Million Y; Feleke T; Tiruneh M
    Ann Clin Microbiol Antimicrob; 2021 Mar; 20(1):16. PubMed ID: 33706775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of and risk factors for intestinal colonisation by multidrug-resistant Gram-negative bacteria in patients with haematological malignancies: A systematic review and meta-analysis.
    Luo H; Chen X; Jiang Z; Yan Q
    Int J Antimicrob Agents; 2024 Jan; 63(1):107043. PubMed ID: 38040318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A high prevalence of multi-drug resistant Gram-negative bacilli in a Nepali tertiary care hospital and associated widespread distribution of Extended-Spectrum Beta-Lactamase (ESBL) and carbapenemase-encoding genes.
    Manandhar S; Zellweger RM; Maharjan N; Dongol S; Prajapati KG; Thwaites G; Basnyat B; Dixit SM; Baker S; Karkey A
    Ann Clin Microbiol Antimicrob; 2020 Oct; 19(1):48. PubMed ID: 33087115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.
    Castanheira M; Huband MD; Mendes RE; Flamm RK
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis.
    Willems RPJ; van Dijk K; Vehreschild MJGT; Biehl LM; Ket JCF; Remmelzwaal S; Vandenbroucke-Grauls CMJE
    Lancet Infect Dis; 2023 Jun; 23(6):719-731. PubMed ID: 36731484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
    Vardakas KZ; Falagas ME
    Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.